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1. Introduction 
Breast cancer is the most common non-cutaneous type of cancer in women and the most 
common cause of cancer-related mortality among women worldwide, with more than 
1,000,000 new cases and more than 410,000 deaths each year (Parkin et al., 2005; Anderson et 
al., 2006; Parkin & Fernandez, 2006). Even when breast cancer mortality is decreasing in 
developed countries due to primary prevention, screening, and improved therapies, there 
were still 130,000 deaths in europe (Boyle & Ferlay, 2005) and 40,000 deaths in US (Ries et 
al., 2008) during 2004. Moreover, in less developed countries breast cancer patients show 
poorer treatment outcomes and increased mortality rates as result of diagnosis at a more 
advanced stage (Boyle, 2005). 
Therapy for breast cancer includes cytotoxic, hormonal, and immunotherapeutic agents. In 
general, these agents induce response rates ranging from 60% to 80% for primary breast 
cancers and about 50% of metastases (Guarneri & Conte, 2004; Gonzalez-Angulo et al., 
2007). However, despite the frecuency of primary responses, the median duration of 
response to chemotherapy is 8 to 14 months (Pusztai & Hortobagyi, 1998). Consequently, 
20% to 70% of patients show recurrent disease within 5 years (Pusztai & Hortobagyi, 1998; 
Pisani et al., 2002; Colleoni et al., 2004). The use of local radiotherapy in addition to 
chemotherapy reduces mortality by 17 to 30% and is particularly beneficial for patients with 
extensive nodal metastasis, which tend to contain a higher absolute number of 
chemotherapy resistant cells (Ragaz, 2009). 
These data indicate that even though current treatments are active at the beginning of 
therapy, progression still occurs in the majority of patients. Furthermore, when recurrence 
appears, resistance to therapy is common increasing the risk of death (Gonzalez-Angulo et 
al., 2007). The failure of current treatments necessitates new approaches. Such approaches 
must consider the potential role of cancer stem cells (CSCs) in the initiation, maintenance, 
and clinical outcome of breast cancers. 
2. Breast cancer stem cells 
The cells within a tumor display functional heterogeneity, with different morphology, 
differentiation grade, proliferation rate, and invasiveness (Heppner & Miller, 1983). Recent 
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studies suggest that the ability of a tumor to proliferate and propagate relies on a small 
population of stem-like cells, called cancer stem cells (CSCs). CSCs share fundamental 
characteristics with normal adult stem cells: they divide asymmetrically producing one stem 
cell and one progenitor cell. In normal stem cells, this allows the continuation of the stem 
cell compartment and starts the production of cells that undergoes multilineage 
differentiation. Similarly, CSCs have the ability to perpetually self-renew and to produce 
tumors comprised of cells with different phenotypes. Since their discovery in leukaemia 
(Bonnet & Dick, 1997), the existence of a subpopulation of CSCs has been corroborated in 
several solid tumours, including breast, brain, colon, pancreas, prostate, lung, and head and 
neck tumors (Glinsky, 2007; Li et al., 2007; Prince et al., 2007; Eramo et al., 2008). 
2.1 Identification and isolation of breast CSCs 
The discovery of CSCs in human breast tumors was reported in 2003 by Al-Hajj and 
collaborators. They discovered a cellular population characterized by cell-surface 
CD44+/CD24-/low/ESA+ markers, and lineage- (lack of expression of CD2, CD3, CD10, CD 
16, CD18, CD31, CD64, and CD140b). As few as 200 of these cells were able to form tumors 
when injected into NOD/SCID mice while tens of thousands of other cells could not (Al-
Hajj et al., 2003). The tumors that were generated recapitulated the phenotypic 
heterogeneity of the initial tumor, containing a minority of CD44+/CD24-/low/lineage- cells 
that can be serially passaged to form new tumors (Al-Hajj et al., 2003). The CD44+/CD24- 
phenotype has been used extensively to identify and isolate cancer cells with increased 
tumorigenicity (Fig. 1). 
Breast CSCs have also been isolated from patient samples after in vitro propagation (Ponti et 
al., 2005) and from breast cancer cell lines (Fillmore & Kuperwasser, 2008).  The breast CSCs 
convey an ability to form mammospheres in culture. Mammosphere culture is a system that 
allows the propagation of mammary epithelial cells in an undifferentiated state, based on 
their ability to proliferate in suspension as non-adherent spheres (Dontu et al., 2003; Dontu 
et al., 2004). Accordingly, the capacity to form mammospheres is increased in early 
progenitor/stem cells. These cells have the ability to differentiate along all three mammary 
epithelial lineages and to generate complex functional structures in reconstituted 3D culture 
systems (Dontu et al., 2003; Dontu et al., 2004). The mammospheres from breast cancer cells 
are enriched in cells with the CD44+/CD24-/low phenotype, and these cells retain tumor-
initiating capability when injected into NOD/SCID mice (Fig. 1). However, only a fraction 
of CD44+/CD24-/low cells is able to form secondary mammospheres (Ponti et al., 2005). 
Consistent with these findings, cancer cell lines that are enriched (90%) in CD44+/CD24-/low 
cells are not more tumorigenic than cell lines that contain only 5% of cells with the same 
phenotype (Fillmore & Kuperwasser, 2008), indicating that only a subgroup within the 
CD44+/CD24-/low cells are self-renewing. 
As only a subpopulation of CD44+/CD24- cells form tumors, additional markers have been 
investigated. Aldehyde dehydrogenase (ALDH) family of cytosolic isoenzymes are 
responsible for oxidizing intracellular aldehydes, leading to the oxidation of retinol to 
retinoic acid, an event that ocurrs in early stem cell differentiation. ALDH1 is the 
predominant ALDH isoform in mammalian cells. Increased ALDH activity has been 
described in human hematopoietic stem cells as well as in cancer stem cells of multiple 
tissues (Hess et al., 2004; Corti et al., 2006). Aldefluor staining for the identification of breast 
CSCs uses an uncharged ALDH substrate, BAAA (BODIPY-aminoacetaldehyde). BAAA is 
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Fig. 1. Increased tumorigenicity of CD44+/CD24- Met-1 mouse breast cancer cells (from Wu 
et al., 2010 J Biol Chem, in press). A) Met-1 cells were separated by immunosorting based on 
the phenotypes CD44+/CD24- or CD44+/CD24+. B) Tumor regeneration after after 
subcutaneous implantation of 1000 sorted cells per mouse. 
taken up by living cells through passive diffusion and converted by intracellular ALDH into  
a negatively charged reaction product BAA- (BODIPY-aminoacetate). BAA- is retained 
inside cells expressing high levels of ALDH, causing them to become brightly fluorescent 
(Christ et al., 2007). Thus, the ALDH-expressing cells can be detected in the green 
fluorescence channel (520-540 nm) of a standard flow cytometer (Fig. 2). Breast tumor cells 
positive for ALDH activity are able to generate tumors in NOD/SCID mice with phenotypic 
characteristics resembling the parental tumor, suggesting that the ALDH+ pool contain the 
CSC population (Ginestier et al., 2007). The cell selection using the CD44+/CD24-/ALDH+ 
phenotype increases the tumorigenicity of breast cancer cells in comparision with 
CD44+/CD24- or ALDH+ cells (Ginestier et al., 2007). 
New strategies to improve the identification and isolation efficiency of breast CSCs have 
been recently reported (Cicalese et al., 2009; Pece et al., 2010; Sajithlal et al., 2010). The 
fluorescent dye PKH26 has been used to identify the fraction of stem cells in normal human 
mammary cells. Briefly, the method consists of labelling the cell membrane with PKH26 and 
then culturing the mammary cells in suspension to form mammospheres. After 7-10 days 
only the slow cycling cells retain the dye and can be sorted based on their PKH26 
fluorescence intensity. The PKH26hi cells (0.2-0.4% of the total cell population) are able to 
form secondary mammospheres, divide asymetrically, express markers of pluripotentiality, 
and can reconstitute a normal mammary epithelium when transplanted into NOD/SCID 
mice, indicating that this population is highly enriched in stem cells (Pece et al., 2010). The 
same strategy has been successfully used to enrich breast CSCs in ErbB2 transgenic mice 
(Cicalese et al., 2009) and from human cancer cell lines (Fig. 3). Furthermore, analysis of the 
expression profile of PKH26hi cells allowed the identification of the CD49f+/DLL1hi/DNERhi 
phenotype as prospective markers of human breast CSCs (Pece et al., 2010). 
CD49f+/DLL1hi/DNERhi cells are present in human breast tumor samples, corresponding to 
1.5-6% of the cancer cells. The CD49f+/DLL1hi/DNERhi fraction is enriched in CSCs, since 
the injection of only 500 of those cells was sufficient to produce tumors in NOD/SCID mice 
(Pece et al., 2010). 
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Fig. 2. Aldefluor assay of MCF-7 and MDA-MB-231 breast cancer cells (Jiao et al., 
unpublished). This assay allows the identification and separation of CSCs based on the 
activity of ALDH. DEAB is an inhibitor of ALDH used to increase specificity of the assay. 
Note that the ALDH+ fraction in MCF-7 cells is almost undetectable. 
www.intechopen.com
Breast Cancer Stem Cells   
 
67 
(A) 
 
(B) 
Fig. 3. PKH26 retention during mammosphere culture (Velasco-Velazquez et al., 
unpublished). A) Hs578T human breast cancer cells cultured in non-adherent conditions for 
7 days (bright field). B) Fluorescence microscopy shows that only a few cells retain a high 
level of PKH26 (arrow). Those cells have properties of CSCs. 
A different approach was recently reported by Sajithlal and collaborators (Sajithlal et al., 
2010). They tagged the CSC population from human cancer cell lines with green fluorescent 
protein (GFP) under the control of the Oct3/4 promoter. In MCF-7 cells only 1% of the 
population expressed GFP, and the large majority of those cells were CD44+/CD24-. GFP+ 
cells were sorted and maintained in culture. Unexpectedly, the CD44+/CD24-/GFP+ 
phenotype remained stable for more than one year, suggesting that the incorporation of the 
promoter blocks CSC differentiation. As predicted, the GFP+ cells were 100-300 times more 
tumorigenic that the rest of tumor cells and displayed an increased resistance to cytotoxic 
drugs. Similar results were found when other breast cancer cell lines were stably transfected 
with the Oct3/4 promoter (Sajithlal et al., 2010). These cell lines may become valuable 
models in the study of CSC biology. 
Other stem cell markers have been used to identify breast CSCs in murine models, including 
CD133 and the β1 integrin subunit (CD29). In tumor cell lines generated form Brca1 
deficient mice, Wright and collaborators found two different populations of potential CSCs: 
one with the previously reported CD44+/CD24- phenotype and the other being CD133+ 
(Wright et al., 2008). Both subpopulations were able to repopulate cell fractions found in the 
parental cell lines, formed in vitro mammospheres, generated tumors in NOD/SCID mice, 
and expressed Oct4, a marker of pluripotency. In a similar manner, subpopulations of 
CD24hiCD29low cells isolated from tumor cell lines exhibit the capacity of self-renewal, 
differentiation and tumorigenicity (Vassilopoulos et al., 2008). One possibility is that these 
cells with different immunophenotypes represent different origins of breast cancer stem 
cells. The CD44+/CD24- population most likely represent basal breast cancer stem cells and 
cells with the CD24hiCD29low signature most likely originate from the mammary luminal 
progenitor cells. These data, together with the fact that CD133 and CD29 have been used in 
the identification of normal and cancer stem cells from different tissues, indicate that CD133 
and CD29 could be used as a marker of mouse breast CSCs. The diversity of mouse breast 
cancer stem cells may provide a tool to elucidate the hierarchy of breast cancer stem cells. 
3. Therapeutic resistance in breast CSCs 
Whether breast CSCs arise from normal stem cells or from progenitor cells that have gained 
the ability for self-renewal remains unclear. However, both of these hypotheses consider 
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that the different phenotypic characteristics of normal and cancerous stem cells are caused 
by genetic alterations that promote changes in the signalling pathways controlling the cell 
cycle, differentiation, and survival. These alterations promote changes in key CSC functions 
that are directly related to the clinical outcome of the tumor. In the case of breast cancer, a 
growing body of evidence indicates that CSCs are more resistant to chemo- and 
radiotherapy than the non-stem tumor cells. Accordingly with the cancer stem cell 
hypothesis, the surviving CSCs will be capable to repopulate treated-tumors and produce 
relapse. Moreover, since mutations can be passed on to all the stem cell’s progeny, it is likely 
that the new tumor will display increased resistance to therapeutic regimens, allowing 
evolution towards malignancy over time. Elucidation of the molecular mechanisms by 
which CSCs survive therapy may identify new targets for breast cancer therapeutic 
intervention. 
3.1 Chemoresistance and mechanisms involved 
The role of chemotherapy in the selection and expansion of breast CSCs has been studied 
using different strategies. The proportion of in vitro self-renewing cancer cells from patients 
who received neoadjuvant chemotherapy has been compared with that of cells isolated from 
chemotherapy-naive patients. Mammosphere formation was 14-fold higher in tumor cells 
from the patients that had received chemotherapy (Yu et al., 2007). Enrichment of CSCs by 
chemotherapy was confirmed by studying paired specimens from patients obtained by 
biopsy prior to chemotherapy and at surgery following neoadjuvant chemotherapy. 
Mammosphere formation and the proportion of CD44+/CD24-/low cells were increased 
approximately 10-fold after chemotherapy (Yu et al., 2007). 
Additional evidence from mouse models supports that exposure to chemotherapeutic 
agents elicits a selective pressure and prevents differentiation of CSCs, increasing the 
proportion of CSC in the tumors. Yu and collaborators studied the properties of tumors 
generated by SKBR3 breast cancer cells after consecutive passage in mice receiving 
epirubicin. Those tumors were highly enriched in CD44+/CD24-/lineage- cells, and were 
able to form 20-fold more mammospheres than cells isolated from tumors generated with 
the parental cell line (Yu et al., 2007). The expansion of the CSC population after drug 
treatment contributes to drug resistance. Mammary tumors from Brca1/p53-mutated mice 
are sensitive to cisplatin, but a few months after treatment, tumors relapse at the same site. 
The proportion of CD29hi/CD24med cells (tumorigenic cells) in tumors that arise after 
cisplatin treatment was 4-fold greater than in untreated primary tumors (Shafee et al., 2008). 
Interestingly, when CD29hi/CD24med cells from relapse tumors were injected into Rag1-/- 
mice, they formed tumors that were only partially sensitive to cisplatin. A second round of 
selection and transplantation further increased the CD29hi/CD24med fraction and generated 
tumors that were completely refractory to cisplatin (Shafee et al., 2008), indicating the 
appearance of cisplatin-resistant progenitor cells. 
3.1.1 Multidrug resistance transporters 
The chemoresistance in breast CSCs is caused partially by the expression of ABC (ATP-
Binding Cassette) transporters. A subpopulation of breast cancer cells with the capability to 
extrude the dye Hoechst 33342 (a measurement of ABC transporters activity) is enriched in 
CSCs (Patrawala et al., 2005; Christgen et al., 2007; Woodward et al., 2007). This 
subpopulation, called “side population” (SP), isolated from Cal-51 cells exhibited a 30-fold 
increased in ABCG2 mRNA expression in comparison to unsorted cells (Christgen et al., 
www.intechopen.com
Breast Cancer Stem Cells   
 
69 
2007). After isolation and expansion, cells from the Cal-51 SP gave rise to a heterogeneous 
mix of SP and non SP cells in a proportion similar to the original cell line, in which the non 
SP cells lacked expression of ABCG2. Similarly, ABCG2 expression declined with in vitro 
differentiation of SKBR3 cells isolated from mouse xenotransplants (Yu et al., 2007). Thus, 
the expression of ABCG2 and the ability to efflux drugs is lost during differentiation of 
CSCs to cancer cells. These data partially explain why primary chemotherapy produces 
responses in the large majority of tumors but is ineffective in eradicating the cells that 
express ABC transporters and CSC properties.  
3.1.2 Stem cell signalling pathways 
Alterations in signalling pathways controlling self-renewal and cell fate, such as HER-2, 
Notch, Wnt, and Hedgehog, also contribute to drug resistance in breast CSCs (see (Charafe-
Jauffret et al., 2008; Kakarala & Wicha, 2008) for recent reviews). For example, HER-2 may 
play a role in regulating breast CSC population. HER2 overexpression in breast cancer cell 
lines increased the CSC population as demonstrated by increased ALDH activity, 
mammosphere formation, tumorigenesis, and expression of stem cell related genes 
(Korkaya et al., 2008). ALDH1 has been reported as a major mediator of resistance to 
cyclophosphamide in CSCs (Dylla et al., 2008), suggesting that HER-2-medited signaling 
may favor resistance. Correspondingly, HER-2 inhibition with trastuzumab reduced by 50% 
the recurrence rate after conventional adjuvant chemotherapy (Slamon & Pegram, 2001). 
HER-2-mediated CSC expansion may involve the activation of the Notch pathway, which 
regulates self-renewal of normal mammary stem cells (Dontu et al., 2004). Notch is 
aberrantly activated in human breast carcinomas (Pece et al., 2004; Stylianou et al., 2006) 
correlating with cyclin D1 overexpression. Notch directly induces cyclin D1 expression and 
Notch correlates with cyclin D1 expression during development (Stahl et al., 2006). HER-2 
induced Notch-1 activation in breast cancer cells by increasing the expression of cyclin D1. 
In turn, cyclin D1 inhibited the expression of the Notch-1 negative regulator Numb (Lindsay 
et al., 2008). In ER-negative breast cancer cells, Notch-1 activation directly promoted the 
transcription of the antiapoptotic gene Survivin (Lee et al., 2008). In turn, increased survivin 
levels may deregulate multiple mitotic checkpoints, contributing to genetic instability (Lens 
et al., 2006) and inhibiting radiation- and drug-induced apoptosis (O'Connor et al., 2002; 
Ghosh et al., 2006). Additional evidence of the role of a Notch/survivin axis in breast CSCs 
survival and resistance include that: i) Notch-1 protects CD44+/CD24-/low breast cancer-
initiating cells from radiation (Phillips et al., 2006); ii) a neutralizing antibody against Notch-
4 reduced mammosphere viability in primary cultures of ductal carcinoma in situ of the 
breast (Farnie et al., 2007); iii) the antiapoptotic protein survivin is overexpressed in breast 
CSC cultures (Ponti et al., 2005); and iv) chemoresitance displayed in CSCs isolated from 
MCF-7 cells is associated with increased expression of Notch-1 (Sajithlal et al., 2010). These 
data suggest that survivin and cyclin D1 may operate as a Notch-regulated cytoprotective 
factors that promote persistence of breast CSCs. 
4. Role of CSCs in breast tumor metastasis 
Metastasis is a highly complex process that comprises several sequential steps, that include 
escape from the primary tumor (intravasation), survival within the circulation, extravasation 
into a secondary site, and sustained growth in a distinct microenvironment (Woodhouse et 
al., 1997; Chambers et al., 2002; Pantel & Brakenhoff, 2004). Several lines of evidence indicate 
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that metastasis is a highly inefficient process. Depending on the experimental model, 0.02- 
0.1% of the cancer cells that reach the circulation can develop macrometastases (Weiss, 1990; 
MacDonald et al., 2002; Allan et al., 2006). Recently, CSCs capable of seeding distant 
metastasis have been identified (Li et al., 2007) supporting the model in which CSCs initiate 
and sustain secondary tumor growth. Accordingly, several authors have proposed a model 
in which CSCs appear as the active source of metastatic spread (Wicha, 2006; Li et al., 2007; 
Goss et al., 2008; Visvader & Lindeman, 2008). 
In agreement with that model, a subpopulation of circulating tumor cells that express stem 
cell markers has been identified in metastatic breast cancer patients and a high percentage of 
CD44+/CD24- tumor cells have been found in metastases. (Balic et al., 2006; Aktas et al., 
2009; Theodoropoulos et al., 2010). Additionally, a gene signature of invasiveness (IGS), 
generated by comparing the gene-expression profile of CD44+/CD24- tumorigenic breast 
cancer cells with that of normal breast epithelium, is strongly associated with metastasis-free 
survival (Liu et al., 2007). Finally, expression of the stem cell marker ALDH in samples of 
inflammatory breast cancer (IBC) correlates with the development of distant metastasis and 
decreased survival (Charafe-Jauffret et al., 2010). 
The ability of breast CSCs to invade and proliferate at the metastatic sites has been studied 
both in vitro and in vivo. CSCs isolated from cancer cell lines exhibited increased 
invasiveness and elevated expression of genes involved in invasion (IL-1α, IL-6, IL-8, 
CXCR4, MMP-1, and UPA) (Sheridan et al., 2006). Accordingly, ALDH+ cells isolated from 
breast cancer cell lines were more migratory and invasive than the ALDH- cells (Charafe-
Jauffret et al., 2009; Croker et al., 2009). Intracardiac injection of ALDH+ cells isolated from 
human breast cancer cell lines to NOD/SCID mice generated metastases at distinct organs; 
in contrast, ALDH- cells produced only occasional metastases limited to lymph nodes 
(Charafe-Jauffret et al., 2009; Charafe-Jauffret et al., 2010). 
Molecular genetic analysis has identified key regulators of the breast cancer stem cell 
phenotype using knockout and transgenic mice including c-Jun (Jiao et al., 2010) , p21CIP 
(Liu et al., 2009), NFκB (Liu et al., 2010 Cancer Res, in press) and the retinal determination 
gene network (RDGN) (Micalizzi et al., 2009); Wu et al., 2010 J Biol Chem, in press). 
Our group has shown that molecular signals that promote “stemness” in cancer cells also 
promote the acquisition of metastatic ability. Using bitransgenic mice encoding a floxed c-
Jun allele and mammary targeted ErbB2 we have reported that the proto-oncogene c-Jun 
 
 
Fig. 4. Schematic representation of c-Jun-mediated cellular migration and CSC expansion via 
induction of SCF and CCL5 (RANTES) production (adapted from Jiao et al. 2010). 
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controls the transcriptional expression of SCF (Stem Cell Factor) and CCL5 (RANTES). 
Reduction in SCF causes a decrease in the proportion of cells expressing breast CSC markers 
and in CSC self-renewal, while c-Jun-mediated expression of CCL5 plays a key role in the 
autocrine control of the migration and invasion of breast cancer cells (Jiao et al., 2010). These 
studies demonstrated that a single cellular proto-oncogene is necessary to both, activate 
signaling pathways that promote features of CSC and maintain the invasive phenotype of 
mammary tumors (Fig. 4).  
5. Targeting CSCs 
The key roles of CSCs in breast cancer biology suggest that new therapies must target these 
cells. The main objective of those therapies would be the eradication of the CSC 
compartment with no harm to other cell types. Eradication of breast CSCs may include 
different strategies as summarized in Table 1. 
Different approaches have been used to overcome ABC transporter-mediated 
chemoresistance. The anthracycline modified drug annamycin, which is not extruded by 
ABC transporters, was toxic to the resistant cell line MCF-7/VP (Perez-Soler et al., 1997). 
The plant alkaloid berberine decreased the expression of the ABCG2 transporter and 
reduced the “side population” of the MCF-7 cell line (Kim et al., 2008), suggesting that 
downregulation of ABC transporters may be useful for targeting breast CSCs. However, the 
ability to target drug transport in CSCs may be difficult since these cells express multiple 
ABC transporters (de Grouw et al., 2006). The use of inhibitors of ABC transporters 
simultaneously with anticancer drugs is an efficient approach to overcome resistance in vitro 
and in animal models (Ozben, 2006). However, clinical trials with this kind of inhibitors 
have shown that they produce serious side effects (Ozben, 2006). High-throughput 
screening identified the ionophore salinomycin as toxic to breast CSCs (Gupta et al., 2009). 
Salinomycin induced capase-independent apoptosis in human cancer cells of different 
origins that display multiple mechanisms of drug resistance, at concentrations that did not 
affected normal cell viability (Fuchs et al., 2009). Subsequent studies showed that 
salinomycin induces a conformational change of the ABC transporter MDR1/ABCB1 that 
reduces its activity (Riccioni et al., 2010). Therefore, salinomycin is particularly effective at 
inducing apoptosis in leukemia cells that display ABC transporter-mediated drug-resistance 
(Fuchs et al., 2010).  
Targeting CSCs through their specific markers was partially succesful in acute myeloid 
leukemia (AML) (Sperr et al., 2005; Tsimberidou et al., 2006). Cytotoxic antibodies directed 
against CD33 (a common marker in leukemic stem cells) induced remission in some 
patients. However, the antibody produced cytopenia due to its effects on normal 
hematopoietic stem cells (Sperr et al., 2005; Tsimberidou et al., 2006). Similarly, a 
monoclonal antibody against CD44 induced terminal differentiation and apoptosis of AML 
cells in engrafted mice (Jin et al., 2006). Anti-CD44 antibodies conjugated with cytotoxic 
drugs or radiolabels have shown to reduce disease progression in breast cancer patients and 
animal models (reviewed by (Platt & Szoka, 2008)). 
 Other potential targets in breast CSC therapy include molecules that participate in self-
renewal and cell fate. Inhibition of Hedgehog signaling in xenografts established from 
pancreatic cancer cell lines reduced the number of ALDH-overexpressing cells (Feldmann et 
al., 2008). The promoters of the MDR, hTERT, and Cox-2 genes are active in breast CSCs. 
Oncolytic adenoviruses driven by these promoters were effective in killing CD44+/CD24-/low 
cells in vitro, and reducing tumor growth in vivo (Bauerschmitz et al., 2008).  
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Interruption of signals generated in the CSC microenvironment using antibodies or soluble 
ligands against adhesion receptors may be useful in CSC targeting. α6-integrin inactivation 
with antibodies or siRNA abrogated mammosphere-forming ability and tumorigenicity of 
breast cancer cells (Cariati et al., 2008). The IL-8 receptor CXCR1 inhibitor repertaxin 
reduced the breast CSC population, producing apotosis in the tumor population, and 
reduced metastasis (Ginestier et al., 2010). 
 
Target in breast CSCs Strategy Example 
Cytotoxic drugs that cannot be extruded by 
ABC transporters 
Annamycin 
Reduce expression 
Berberine 
siRNAs 
ABC transporters 
ABC transporters inhibitors Salinomycin 
Membrane markers 
Antibodies conjugated with drugs or 
radioligands 
Anti-CD44 
Small molecule inhibitors --- 
Reduce expression siRNAs Intracellular 
signalling molecules 
Oncolytic virus activated by specific promoters 
MDR 
promoter 
Small molecule receptor antagonists Repertaxin 
Blocking antibodies 
Anti-α6 
integrin 
Signals from the 
microenvironment 
Blocking soluble ligands Soluble HA 
Others Metabolic alteration? Metformin 
Table 1. Strategies for the eradication of CSCs.  
Metformin is an anti-diabetic drug that has found to reduce breast cancer incidence and 
improve survival of breast cancer patients with type 2 diabetics (Vazquez-Martin et al., 
2010a). Recent studies showed that the drug metformin selectively reduces the breast CSC 
population. In human breast cancer cell lines, metformin reduced the CD44+/CD24- 
population and their ability to form mammospheres (Hirsch et al., 2009). In a xenograft mice 
model, concurrent treatment with metformin and doxorubicin reduced tumor mass much 
more effectively than either drug alone (Hirsch et al., 2009). Metformin also targeted 
traztasumab-resistant CSCs that overexpress HER-2 (Vazquez-Martin et al., 2010b). The 
mechanism involved in the metformin effects on CSCs is unclear, but seem to be associated 
with its activator effect on AMP-activated kinase (AMPK) (Vazquez-Martin et al., 2010a). 
AMPK phosphorylates and inhibits Acetyl CoA carboxylase (ACACA), the limiting enzyme 
of the fatty acid synthesis. Thus, metformin may be affecting cancer cell metabolism and 
functioning of lipid raft platforms (Vazquez-Martin et al., 2010a). 
6. Conclusions 
CSCs have a central role in breast cancer progression since they are involved in tumorigenesis, 
therapy response, and metastasis formation. Diverse methodologies based on their phenotype 
or specific cellular functions have been described to isolate mouse and human breast CSCs. 
Combinations of these methodologies improve the efficiency of purification.  
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Development of new therapies for targeting and eradication of breast CSCs must consider 
both, the differences between CSCs cells and the rest of the tumor cells and the pathways 
shared between CSCs and normal stem cells. Elucidation of the specific mechanisms by 
which CSCs survive chemotherapy, regulate self-renewal, and interact with their primary 
and metastatic niches will be useful for the design of new therapeutic alternatives. Such 
approaches may become the basis for the generation of effective and clinically applicable 
therapies that prevent disease relapse, metastasis and enhance patient survival. 
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